Physician profile
Mohammad B Khan
NPI 1659374866
$13,061.90
in general payments reported to CMS, 2019-2025
67 companies · $2,067 in 2025
The $2,067 reported for 2025 was more than what 81% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $1,813 · 2021: $2,112 · 2022: $1,946 · 2023: $1,697 · 2024: $2,048 · 2025: $2,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,236 · Education: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,236.00 |
| Education | $576.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $2,009.87 | 2019-2025 | |
| Ucb, INC. | $1,232.61 | 2019-2025 | Briviact, Nayzilam |
| Harmony Biosciences LLC | $931.39 | 2020-2025 | Wakix |
| Eisai INC. | $893.26 | 2020-2025 | |
| Pfizer INC. | $685.30 | 2023-2025 | |
| Lilly USA, LLC | $643.66 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Sunovion Pharmaceuticals INC. | $569.58 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $482.09 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $369.88 | 2019-2025 | |
| Sk Life Science, INC. | $367.67 | 2020-2025 | |
| Abbvie INC. | $358.54 | 2021-2025 | |
| Amgen INC. | $343.88 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $309.52 | 2019-2022 | |
| Tg Therapeutics, INC. | $284.42 | 2024-2025 | |
| Emd Serono, INC. | $269.29 | 2019-2020 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $243.58 | 2020-2024 | Ajovy, Austedo, Austedo Xr |
| Biogen, INC. | $235.65 | 2019-2025 | Vumerity, Tysabri |
| Biohaven Pharmaceutical Holding Company LTD. | $231.18 | 2022 | |
| Lundbeck LLC | $190.78 | 2020-2025 | Vyepti, Rexulti |
| Upsher-Smith Laboratories LLC | $172.86 | 2020-2022 | |
| Neurelis, INC. | $156.15 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $133.35 | 2022-2025 | Ingrezza |
| Greenwich Biosciences, INC. | $125.00 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $114.73 | 2022-2023 | Spritam |
| Allergan, INC. | $113.69 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $101.68 | 2023 | Aptiom |
| Amneal Pharmaceuticals LLC | $98.50 | 2019-2024 | Rytary |
| Axsome Therapeutics, INC. | $77.90 | 2024 | Sunosi |
| Edw Pharma, INC. | $77.29 | 2023 | Tiglutik |
| Otsuka America Pharmaceutical, INC. | $67.77 | 2023-2024 | Nuedexta, Abilify Mycite |
| Kyowa Kirin, INC. | $64.99 | 2020-2024 | Nourianz |
| Philips North America LLC | $62.75 | 2019-2025 | Patient Interface Software |
| Argenx US, INC. | $62.33 | 2023 | Vyvgart |
| Avadel Cns Pharmaceuticals, LLC | $58.67 | 2024-2025 | Lumryz |
| Mallinckrodt Enterprises LLC | $54.33 | 2019 | |
| Impel Pharmaceuticals INC. | $53.41 | 2022-2023 | Trudhesa |
| Abbott Laboratories | $47.44 | 2020-2022 | |
| Shockwave Medical, INC | $47.28 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inspire Medical Systems, INC. | $45.93 | 2023 | Inspire |
| Livanova USA, INC. | $45.17 | 2019-2021 | |
| Corium, LLC | $42.40 | 2022-2023 | Adlarity |
| Arbor Pharmaceuticals, INC. | $42.06 | 2019-2021 | |
| Medtronic USA, INC. | $37.72 | 2019-2020 | |
| Tanabe Pharma America, INC. | $32.91 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.47 | 2020 | |
| Nevro Corp. | $25.60 | 2021 | |
| Genentech USA, INC. | $25.10 | 2025 | Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $24.76 | 2023 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $24.57 | 2019 | |
| Merck Sharp & Dohme LLC | $23.65 | 2021 | |
| Saluda Medical Americas, INC. | $22.96 | 2023 | Evoke Scs |
| Zoll Respicardia, INC. | $22.68 | 2024 | Remede System |
| Otto Bock Healthcare LP | $22.59 | 2021 | |
| Medtronic, INC. | $21.98 | 2024 | Intellis Adaptivestim |
| Almatica Pharma LLC | $21.82 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.89 | 2024 | Wainua |
| Alfasigma USA, INC. | $20.45 | 2021 | |
| Globus Medical, INC. | $20.05 | 2025 | Senza |
| Genzyme Corporation | $18.97 | 2019 | |
| Celgene Corporation | $18.46 | 2025 | Zeposia |
| Promius Pharma LLC | $17.96 | 2019 | |
| Horizon Therapeutics Plc | $17.47 | 2022 | |
| Shire North American Group INC | $17.44 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.91 | 2023 | Quviviq |
| Ge Healthcare | $14.82 | 2024 | |
| Azurity Pharmaceuticals, INC. | $14.52 | 2023 | Horizant |
| Bausch Health US, LLC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.